- Healthcare Professionals
- Therapies and Procedures
- Concomitant Surgical Ablation Therapy
- Ablation Sensing Unit & Switch Matrix
- cryoFORM® Cryoablation Probe
- cryoICE® BOX V6
- cryoICE® Cryoablation Probes
- Isolator® Linear Pen
- Isolator® Synergy™ Access® Clamp
- Isolator® Synergy™ Clamps (OLL2/OSL2)
- Isolator® Transpolar Pen (MAX3)
- Isolator® Synergy™ EnCompass® Clamp
- Multifunctional Ablation Generator (MAG)
- Hybrid AF™ Therapy
- Hybrid Total Thoracoscopic Therapy
- Left Atrial Appendage Management
- Cryo Nerve Block Therapy
- Concomitant Surgical Ablation Therapy
- Education & Training
- Clinical Evidence
- Product Labeling
- Resources
- Society Guidelines
- Therapies and Procedures
- Patients & Caregivers
- About AtriCure
Isolator Synergy Clamps (OLL2/OSL2)
This product may not be available in your specific country. Contact your local AtriCure representative to check availability.
The Isolator Synergy™ Ablation Clamps feature two pairs of opposing dual electrodes, an in-line handle with syringe-type actuation and button release mechanisms. The Isolator Synergy™ Ablation Clamp requires the use of the AtriCure Switch Box (ASB3) and Ablation Sensing Unit (ASU3).
To ensure that the RF energy is delivered uniformly across the cardiac tissue ablation zone, the clamp has a unique parallel jaw closing system. Each jaw contains two sets of gold-plated pulsating electrodes that ensure ablation takes place in the deepest part of the tissue first.
The clamp continuously monitors tissue impedance directly and adjusts the power multiple times per second. These unique and advanced features ensure that each ablation is transmural, delivered safely and is tissue specific thus maximizing the ability to promote better clinical outcomes.
| Product Code(s): |
|---|
OLL2 |
OSL2 |
The Isolator Synergy™ Ablation Clamps feature two pairs of opposing dual electrodes, an in-line handle with syringe-type actuation and button release mechanisms. The Isolator Synergy™ Ablation Clamp requires the use of the AtriCure Switch Box (ASB3) and Ablation Sensing Unit (ASU3).
To ensure that the RF energy is delivered uniformly across the cardiac tissue ablation zone, the clamp has a unique parallel jaw closing system. Each jaw contains two sets of gold-plated pulsating electrodes that ensure ablation takes place in the deepest part of the tissue first.
The clamp continuously monitors tissue impedance directly and adjusts the power multiple times per second. These unique and advanced features ensure that each ablation is transmural, delivered safely and is tissue specific thus maximizing the ability to promote better clinical outcomes.
| Product Code(s): |
|---|
OLL2 |
OSL2 |
Indication (Brazil, Chile, Costa Rica, EU Region, Kuwait, New Zealand, Saudi Arabia, Serbia, Taiwan, UAE, UK)
The AtriCure Bipolar (Transpolar) System is indicated for ablation and coagulation of soft tissue in general, ENT, thoracic, urological, gynecological surgical procedures and ablation of cardiac tissue during surgery including pulmonary vein isolation and atrial connecting lesions for the Maze procedure for the treatment of cardiac arrhythmias, including atrial fibrillation.
Indication (Australia, Belarus, Costa Rica, Korea, Russia, South Africa)
The AtriCure Bipolar (Transpolar) System is intended to ablate cardiac tissue during surgery.
Indication (Argentina, Colombia, Hong Kong)
The AtriCure Bipolar (Transpolar) System is intended to ablate soft tissue during general surgical procedures.
Indication (China)
Ablation of cardiac tissue.
Indication (Japan)
This device is intended for use in ablation of cardiac tissue during surgery by use of high-frequency current.
Indication (Singapore)
The AtriCure Bipolar (Transpolar) System is indicated for ablation of cardiac tissue during surgery including pulmonary vein isolation and atrial connecting lesions for the treatment of atrial fibrillation.
Indication (Canada)
The AtriCure Synergy Ablation System is intended to ablate cardiac tissue for the treatment of persistent atrial fibrillation (sustained beyond seven days, or lasting less than seven days but necessitating pharmacologic or electrical cardioversion) or longstanding persistent atrial fibrillation (continuous atrial fibrillation of greater than one year duration) in patients who are undergoing open concomitant coronary artery bypass grafting and/or valve replacement or repair.
Available Downloads
PM-INTL-2676A-0525-G
© 2024 Atricure, Inc. All Rights Reserved.
